SANOFI’S BLOOD THERAPY (ADD; 16% UPSIDE)
22/05/18 -"In our last piece on Sanofi, we juxtaposed it with AstraZeneca, which emerged as the winner based on its R&D strength and pro-activeness, while Sanofi was suffering from a lack of direction, ..."
Pages
75
Language
English
Published on
22/05/18
You may also be interested by these reports :
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...